New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology annual meeting, including: Aleta, Allovir, Alx, Beigene, Bio-Path, Bluebird, BMS, Carsgen, Catamaran, CDR-Life, Cellectis, Celularity, Corvus, CTI, Epizyme, Forma, GBT, Genentech, Harpoon, Ichnos, IGM, Imago, Immunicum, Immunogen, Incyte, Janssen, Jazz, Kite, Loxo, Maat, Morphosys, Neoleukin, Novartis, Orca, Precision, Protagonist, Regeneron, Samsung, Sana, Schrodinger, Servier, Silence, Syndax, Tessa, Vincerx, X4.

Core presentations at the 63rd meeting of the annual American Society of Hematology (ASH) began Saturday morning with the presentation of three studies focused on non-Hodgkin lymphomas and one on multiple myeloma (MM). Each approach used the immune system as a cancer fighter but employed different mechanisms of action. Two of them successfully used CAR T therapies as treatment.